4DMedical (ASX:4DX) announced a leap in its global commercial strategy, headlined by a new strategic contract with pharmaceutical giant GlaxoSmithKline.
Under the one-year agreement commencing May 1, 4DMedical will provide its proprietary lung imaging analytics to support GSK’s pulmonary drug development and clinical research.
By delivering sensitive, quantitative biomarkers, the technology aims to enhance trial efficiency and improve longitudinal disease assessment, further cementing the company’s role as a preferred provider for the world’s leading biopharmaceutical firms.
The announcement coincides with a breakthrough in regulatory expansion, as 4DMedical’s CT:VQ technology received UKCA certification.
The clearance grants clinical access to the United Kingdom’s diagnostic imaging market, where millions of chest CT scans are performed annually.
This follows recent CE Mark certification, significantly broadening the company's European footprint.
Furthermore, 4DMedical has gained Canadian clearance for its coronary artery calcium analysis, timed with its participation at the Canadian Association of Radiologists annual scientific meeting.
At the time of reporting, 4DMedical’s share price was $5.88.